Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.
The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.
|Neuroendocrine Tumors Carcinoid Tumors Neuroblastoma Medulloblastoma||Drug: 68Ga-DOTATOC PET/CT||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
|Official Title:||Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors|
- Evaluate impact of 68Gallium-DOTATOC PET/CT imaging on tumor management [ Time Frame: 36 months ]Referring physicians will be asked to fill out pre-PET and post-PET scan forms to provide information on the management and treatment strategy of the patient before the PET-CT scan and after the information from the PET-CT study is available. This is the same methodology used in the National Oncologic PET Registry study; change in management strategy criteria are modified for the specific treatment strategies used in NET (Table 2).
|Study Start Date:||September 2015|
|Estimated Study Completion Date:||June 2021|
|Estimated Primary Completion Date:||June 2019 (Final data collection date for primary outcome measure)|
Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
Drug: 68Ga-DOTATOC PET/CT
Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
Please refer to this study by its ClinicalTrials.gov identifier: NCT02441062
|Contact: Mary S O'Dorisio, MD, PhDemail@example.com|
|United States, Iowa|
|University of Iowa Hospitals and Clinics||Recruiting|
|Iowa City, Iowa, United States, 52242|
|Principal Investigator: Mary S O'Dorisio, MD, PhD|
|Principal Investigator:||Mary S O'Dorisio, MD, PhD||University of Iowa|